GSK’s two-drug HIV treatment meets main goal in late stage studies

(Reuters) – GlaxoSmithKline said on Thursday that its two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies.

FILE PHOTO: The GlaxoSmithKline (GSK) logo is seen on top of GSK Asia House in Singapore, March 21, 2018. Picture taken March 21, 2018. REUTERS/Loriene Perera

The studies were designed to evaluate the safety and efficacy of the two-drug combination, which is aimed at lessening the side effect of current treatments that combine Cost of triamcinolone injection three or four medicines.

The safety results for the imuran purchase new HIV treatment, a fixed-dose once-daily tablet that combines two previously approved drugs, dolutegravir and rilpivirine, were consistent with the product labeling for the medicines, GSKai??i??s majority owned ViiV Healthcare said.

Reporting by Arathy S Nair in Bengaluru; Editing by Alexander Smith